- Home
- VSCO vs BLTE Comparison
VSCO vs BLTE Comparison
Compare VSCO & BLTE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VSCO
- BLTE
- Stock Information
- Founded
- VSCO 1977
- BLTE 2018
- Country
- VSCO United States
- BLTE United States
- Employees
- VSCO N/A
- BLTE N/A
- Industry
- VSCO Clothing/Shoe/Accessory Stores
- BLTE Biotechnology: Pharmaceutical Preparations
- Sector
- VSCO Consumer Discretionary
- BLTE Health Care
- Exchange
- VSCO Nasdaq
- BLTE Nasdaq
- Market Cap
- VSCO 1.9B
- BLTE 2.1B
- IPO Year
- VSCO N/A
- BLTE 2022
- Fundamental
- Price
- VSCO $22.13
- BLTE $59.67
- Analyst Decision
- VSCO Hold
- BLTE Strong Buy
- Analyst Count
- VSCO 12
- BLTE 4
- Target Price
- VSCO $27.83
- BLTE $96.67
- AVG Volume (30 Days)
- VSCO 3.4M
- BLTE 32.6K
- Earning Date
- VSCO 06-11-2025
- BLTE 05-13-2025
- Dividend Yield
- VSCO N/A
- BLTE N/A
- EPS Growth
- VSCO 47.48
- BLTE N/A
- EPS
- VSCO 2.05
- BLTE N/A
- Revenue
- VSCO $6,230,000,000.00
- BLTE N/A
- Revenue This Year
- VSCO $1.94
- BLTE N/A
- Revenue Next Year
- VSCO $1.84
- BLTE N/A
- P/E Ratio
- VSCO $10.81
- BLTE N/A
- Revenue Growth
- VSCO 0.78
- BLTE N/A
- 52 Week Low
- VSCO $13.76
- BLTE $43.70
- 52 Week High
- VSCO $48.73
- BLTE $86.53
- Technical
- Relative Strength Index (RSI)
- VSCO 56.55
- BLTE 41.67
- Support Level
- VSCO $19.68
- BLTE $63.46
- Resistance Level
- VSCO $21.52
- BLTE $65.92
- Average True Range (ATR)
- VSCO 1.13
- BLTE 2.60
- MACD
- VSCO -0.19
- BLTE -0.33
- Stochastic Oscillator
- VSCO 59.18
- BLTE 0.07
About VSCO Victorias Secret & Co.
Victoria's Secret & Co is a retailer of women's intimate and other apparel and beauty products marketed under the Victoria's Secret, PINK, and Adore Me brand names. It also includes the merchandise sourcing and production function serving the Company and its international partners. The Company operates as a single segment designed to serve customers seamlessly through stores and online channels.
About BLTE Belite Bio Inc
Belite Bio Inc is a clinical-stage biopharmaceutical drug development company focused on novel therapeutics targeting untreatable eye diseases involving retinal degeneration such as atrophic age-related macular degeneration and autosomal recessive Stargardt disease or STGD1, both of which progressively to permanent blindness, and metabolic diseases such as non-alcoholic fatty liver disease, or NAFLD, nonalcoholic steatohepatitis, or NASH, type 2 diabetes, or T2D, and gout.